Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 63Lymphoma 35Neutropenia 30Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Non-Hodgkin 18Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 13Hodgkin Disease 13Sarcoma 11Multiple Myeloma 11Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Leukemia 10Burkitt Lymphoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Triple Negative Breast Neoplasms 8Lung Neoplasms 8Rhabdomyosarcoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Chemotherapy-induced Neutropenia 7Central Nervous System Neoplasms 6Breast Neoplasms, Male 6Testicular Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Lymphoma, B-Cell, Marginal Zone 5Fallopian Tube Neoplasms 5Carcinoma, Ovarian Epithelial 5Urinary Bladder Neoplasms 4

Interventions

Tamoxifen 4Exercise 3pyrotinib 2abemaciclib 2Paclitaxel 2Metformin 2Letrozole 2Cyclophosphamide 2Control Groups 2Capecitabine 2Bupivacaine 2Aromatase Inhibitors 2pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1palbociclib 1iniparib 1exemestane 1durvalumab 1darolutamide 1Yoga 1Waiting Lists 1Vitamin D 1Tretinoin 1Trastuzumab 1Tocopherols 1Thioctic Acid 1Standard of Care 1Sodium Chloride 1Self-Help Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Cancer Female × pegfilgrastim × Clear all
NCT03381417 2018-01-02

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 3 Completed
128 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡